FDA Guidance on IVD Validation for Emerging Pathogens 2026

The U.S. Food and Drug Administration (FDA) issued final guidance on November 10, 2026, titled "Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency." This document provides non-binding recommendations to help manufacturers prepare in vitro diagnostic devices (IVDs) for use during declared public health emergencies. It applies to data submitted in pre-Emergency Use Authorization (pre-EUA) packages, EUA requests, or tests offered under applicable enforcement discretion policies.

Background and Purpose of the Guidance

The guidance responds to lessons from prior emergencies, including independent assessments of the FDA's COVID-19 response. A 2021 Booz Allen Hamilton report recommended developing a framework for validating diagnostic tests for emerging pathogens during declared public health emergencies. A 2022 HHS Office of the Inspector General report suggested creating EUA templates for future novel pathogen outbreaks.

During the COVID-19 and mpox responses, the FDA issued enforcement discretion policies to expand testing capacity rapidly. The agency emphasizes that all tests—whether authorized under EUA or offered under such policies—must be appropriately validated. The FDA may take action against tests lacking suitable validation.

The final guidance updates a draft issued January 7, 2025, incorporating public comments to streamline recommendations, add flexibility, and focus on the most important information needed during emergencies.

Source: Alston & Bird Health Care Week in Review

Source: CLP Magazine summary

Scope of the Guidance

This guidance covers diagnostic tests, such as molecular or antigen tests, intended to detect a pathogen to aid in diagnosing a serious or life-threatening infectious disease. It applies during an applicable declaration under Section 564 of the Federal Food, Drug, and Cosmetic Act. Tests may be designed for CLIA-certified laboratories, point-of-care sites, or home use.

Serology and antibody tests fall outside the scope. The recommendations reflect a lower evidence standard than the "effectiveness" requirement for full product approvals, consistent with the "may be effective" criterion for EUAs.

Source: FDA official page

Source: Federal Register notice

Clinical Performance Evaluation Recommendations

The guidance outlines expectations for clinical performance studies. When natural clinical specimens and suitable comparators are available, at least 30 positive and 30 negative specimens from the intended use population are typically adequate for viral nucleic acid tests built on established, highly sensitive technology.

A prospective, all-comers study using natural specimens in the intended use environment is preferred. In early outbreak stages when natural specimens are unavailable, archived specimens or contrived samples may be acceptable. Synthetic RNA is generally preferred over synthetic DNA for RNA viruses.

Authorizations based on contrived samples would likely require post-authorization clinical performance evaluation with natural patient specimens once feasible. Data analysis typically involves calculating positive and negative percent agreement against a highly sensitive comparator, with 95% confidence intervals using the Wilson Score method.

The final guidance provides flexibility: the number of samples and study design depend on factors such as the target pathogen, test type, specimen availability, comparator methods, outbreak stage, and testing needs.

Source: RAPS regulatory news

Source: FDA guidance PDF

Analytical Validation Testing

The final guidance reduces the core analytical tests developers must conduct from 15 to five key areas:

  • Limit of detection (LoD) as analytical sensitivity, confirmed with at least 20 replicates at the preliminary limit.
  • Inclusivity (analytical reactivity), evaluated through in silico analysis aiming for 100% nucleotide sequence identity, supplemented by wet testing of variants when available, with monthly re-evaluation.
  • Specimen stability studies, which may follow CDC specifications or include contrived positive specimens near the LoD and at least 10 negative specimens.
  • Basic safety, software validation, cybersecurity, and electromagnetic compatibility (EMC) testing.
  • Usability, user comprehension, and flex studies.

Additional testing, such as high-dose hook effect evaluation for antigen tests or carry-over testing, may be warranted in specific cases. Simulated matrices should not be used in LoD studies.

Source: RAPS article on reduced testing

Change Protocols and Test-Type Considerations

Manufacturers may develop change protocols for future modifications, such as adding instruments or collection devices. Changes made under an included protocol are considered covered by the initial authorization.

The guidance includes additional considerations for multi-analyte panels, home specimen collection and home-use tests, and point-of-care (POC) tests. It stresses flexibility for different outbreak stages and test technologies.

Implications for Test Developers and Public Health Readiness

This guidance helps manufacturers prepare validation strategies in advance of future outbreaks. By clarifying expectations for clinical and analytical data, it supports faster, more reliable test development during emergencies while maintaining appropriate safeguards.

Developers should review the associated general IVD EUA/pre-EUA template available on the FDA website. Early engagement with the FDA is encouraged when alternative validation approaches are needed.

Public health readiness benefits from having validated tests available quickly. The framework addresses uncertainty inherent in outbreaks by allowing adjusted approaches based on available evidence.

Practical Steps for Stakeholders

Test developers should:

  1. Assess whether their IVD falls within scope (molecular or antigen tests for serious pathogens; excludes serology).
  2. Plan clinical performance studies with at least 30 positive and 30 negative specimens when feasible, or prepare for post-authorization studies if using contrived samples.
  3. Conduct the five core analytical validation tests with appropriate replicates and controls.
  4. Consider including a change protocol in submissions.
  5. Monitor variant inclusivity on an ongoing basis.

Healthcare providers and laboratories should continue to rely on authorized or appropriately validated tests during emergencies.

Limitations and Non-Binding Nature

All recommendations in the guidance are non-binding. Manufacturers may use alternative approaches if they satisfy applicable statutes and regulations. The document does not establish legally enforceable responsibilities.

For the most current information, stakeholders should consult the official FDA guidance document and related templates directly.

Use official FDA and CDC updates for information about diagnostic testing during public health emergencies.

References

Trending

Recommended

Dr. Peter AttiaDr. Peter Attia

Medicare Advantage in Rural Counties for 2027

Medicare Advantage plan availability varies widely by county in 2027. Learn how insurer participation and provider networks may affect choices for older adults in rural US areas, with guidance on comparing options.

18/11/20266 min read
Dr. Peter AttiaDr. Peter Attia

FDA Class II Nasal Congestion Device 2026

FDA classified the external mechanical stimulator for nasal congestion relief as a Class II device in November 2026. Learn what this means for oversight, special controls, 510(k) requirements, and consumer considerations.

18/11/20266 min read
Dr. Peter AttiaDr. Peter Attia

CDC Texas HIV Prevention Funding 2026 Changes

Learn about the CDC ending $29.2 million in Texas HIV prevention grants for community organizations. Find what services may be affected and where to access testing and support.

18/11/20266 min read

Share this article: